Side-by-side · Research reference
5-Amino-1MQvsSermorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BPhase 3Reviewed14/43 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Sermorelin
GHRH 1-29 fragment · Short-acting
SQ · Pre-sleep · 1×/day
01Mechanism of Action
Parameter
5-Amino-1MQ
Sermorelin
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
Pituitary GHRH receptorWalker 1994
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
—
Yes — short pulse preserves feedback
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Sermorelin
Standard dose
100–200 mg / day oralNeelakantan 2018
Anecdotal community range; murine doses scaled.
100–500 mcg per injectionMolteno 2013
Frequency
Once daily, fasted
Once daily, pre-sleep
Lower / starter dose
50 mg / day
100 mcg per dose
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Duration
8–12 weeks per cycle
8–12 weeks per cycle
Form
Oral capsule
—
Timing
Morning fasted preferred
Pre-sleep, fasted preferred
Half-life
Hours (estimated; no human PK published)
~12 min (plasma)Molteno 2013
Shorter than tesamorelin (~26 min) — simpler GHRH analogue.
Reconstitution
—
Bacteriostatic water
04Side Effects & Safety
Parameter
5-Amino-1MQ
Sermorelin
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
—
Cancer risk
Unclear — NNMT also studied in oncology contexts
Contraindicated in active malignancy (GH/IGF-1 axis)
Pregnancy / OB
Avoid
Avoid
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Injection site reaction
—
Mild erythema, transient pain
Flushing / headache
—
Common transient effect
IGF-1 elevation
—
Modest at standard doses
Glucose handling
—
Generally neutral
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Sermorelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Sermorelin
- ·Untreated diabetes
05Administration Protocol
Parameter
5-Amino-1MQ
Sermorelin
1. Form
Oral capsule. No injection.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Administration
Take with water, fasted preferred.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Morning fasted.
Pre-sleep, fasted.
4. Storage
Room temp ≤25 °C, dry place.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Caveat
Monitor B-vitamin status with chronic use.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
5-Amino-1MQ
— no documented stacks
Sermorelin
+ Ipamorelin
StrongSermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.
- Sermorelin
- 200–300 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition